Summary
Kewaunee designs lab furniture for research and healthcare. Recent margin improvements and strong backlog suggest recovery potential, but high leverage and inconsistent sales require caution. Suitable for value investors tolerant of cyclical risks.
Bull Case
Kewaunee’s 6.8x P/E dramatically undervalues a turnaround story – with $159M backlog converting to sales, margin expansion from operational improvements, and potential re-rating as debt reduces. The lab equipment market’s 5.8% CAGR through 2030 provides tailwinds.
Bear Case
At 46x book value, the stock prices in flawless execution despite: 1) 4 consecutive quarters of revenue declines, 2) CFO selling shares, 3) 23% sales drop in core markets last quarter. High debt could force equity dilution if rates rise further.
Recent News
- Q2 FY25 earnings rose 8.6% YoY to $1.01/share despite sales decline, driven by cost controls and stable domestic demand (Zacks, Dec 2024).
- CFO sold $74K in shares at $59.25/share in Jan 2025, representing ~1.5% of position (Benzinga).
- Order backlog reached $159.4M as of Jul 2024 (+19% YoY), but international segment challenges persist (Zacks Initiation, Sep 2024).
Financial Analysis
- Gross margins improved significantly from 14-16% (FY2023) to 25-29% in recent quarters, indicating better pricing/cost control.
- Leverage remains elevated with Debt/Equity at 1.84x as of Jan 2024, though improved from 2.14x in FY2023.
- Domestic sales stability contrasts with volatile international performance – India shipments delayed in Q1 FY25.
- Undervalued metrics: P/E 6.8x vs industry ~20x, P/S 0.7x vs sector median 1.5x.
- Strong liquidity (Current Ratio 2.64x) supports operations amid cyclical demand.
- ROE improved to 20.1% in Q2 FY24 from negative territory previously, showing capital efficiency gains.
Improving margins and backlog suggest operational turnaround, but reliance on lumpy lab equipment capex cycles creates revenue volatility. Low valuation multiples price in risks from leveraged balance sheet (Debt/Equity 1.8x) and concentrated industrial exposure.
Screener Ratings
Compare over 5500 companies with our screener ratings!
Overall: 6
Value: 8
Growth: 4
Dividend Income: 2
Defensive: 5
Competitive Advantage: 3
S.W.O.T. Analysis
Strengths:
- Strong backlog ($159M) provides visibility
- Improved operational efficiency (ROE 20%)
- Low beta (0.735) reduces portfolio volatility
Weaknesses:
- Declining sales (-23% YoY in Q3 FY24)
- Dependence on cyclical R&D spending
- Thin dividend history (no current yield)
Opportunities:
- NIH budget increases driving lab funding
- Modular lab design trends
- International expansion (India delayed)
Threats:
- Raw material inflation (steel +25% YoY)
- Debt refinancing risk (rising rates)
- Insider selling signals
Industry Overview
Threat of New Competitors: Moderate – Specialized manufacturing capabilities and regulatory certifications create barriers, but fragmented $8B lab equipment market allows niche entrants.
Competition Among Existing Firms: High – Competes with Thermo Fisher, Danaher in some segments. Price competition mitigated by customization needs.
Suppliers’ Bargaining Power: Low – Steel/aluminum inputs are commoditized. Multiple sourcing options available.
Buyers’ Bargaining Power: Moderate-High – Universities/government labs (30% of sales) have budget constraints but value long-term vendor relationships.
Threat of Substitute Products: Low – Lab furniture requires compliance with safety standards, limiting alternative solutions.
Competitive Advantage
Cost Advantage: Limited – No scale vs larger competitors. Gross margins below industry average.
Intangible Assets: Moderate – 110+ years in business with reputational edge in custom lab solutions.
Network Effect: None – Products don’t become more valuable with user growth.
Switching Costs: Moderate – Retrofitting labs to new vendor specs can be disruptive for clients.
Supporting Data
You can find supporting data that is derived from company filings and other reputable sources here. It was provided to the AI to generate this report and you can use it to verify the analysis. This supporting data is not AI generated but may still contain errors.
Warning: This document has been generated by an advanced customised AI prompted with financial data derived from company filings and other reputable sources. The process is specifically designed to minimise hallucinations, however the output is not 100% reliable. It is essential to check any information in this document before relying on it for financial decisions. You can find the underlying data used here.
Legal Disclaimer
The information contained on this website and associated documents, including all text, data, analyses, opinions, and forward-looking statements, is provided solely for general informational purposes and does not constitute financial, investment, legal, or tax advice. The content has been generated by an artificial intelligence tool using publicly available data and company filings. Although every effort has been made to ensure accuracy, the information is provided “as is” without any warranty—express or implied—of completeness, accuracy, reliability, or suitability for any purpose.
Not Regulated Advice
No FCA Authorization: We are not authorized or regulated by the Financial Conduct Authority (FCA) or any other financial regulatory body to offer investment advice or recommendations. Nothing in this report should be construed as a solicitation, recommendation, or endorsement to buy, sell, or hold any security or financial instrument.
Independent Decision-Making: Investors are strongly encouraged to conduct their own research and consult with a licensed financial advisor or other professional before making any financial decisions. Reliance on the information provided herein is solely at your own risk.
Forward-Looking Statements
This report may contain forward-looking statements, which are based on current expectations, assumptions, and projections that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. We do not undertake any obligation to update or revise any forward-looking statements in light of new information or future developments.
Limitation of Liability
Under no circumstances shall Aipha.io or its affiliates, employees, or agents be liable for any direct, indirect, incidental, consequential, or other damages arising out of or in connection with the use of, or reliance on, the information contained in this report—even if advised of the possibility of such damages. This includes, without limitation, any loss of profit, revenue, or data.
Use at Your Own Risk
By using this report, you acknowledge that you have read and understood this disclaimer and agree that any reliance on the information provided is at your own risk. [Your Company Name/Aipha.io] expressly disclaims any and all liability for any loss or damage of any kind incurred as a result of any use of this report.